Inflammatory Breast Cancer Clinical Trial
Official title:
A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Current guidelines as those from the AGO-Breast commission recommend for neoadjuvant breast
cancer patients either a sequence of 4 cycles EC followed by 4 cycles of a taxane or 6 cycles
of TAC based on previous large scale studies.
Treatment of patients with HER2-positive disease should include also simultaneous application
of trastuzumab.
Solvent-based taxanes (paclitaxel, docetaxel) cause severe toxicities not only by the active
agents itself but also by the solvents like cremophor. Nab-paclitaxel (Abraxane®) is a
solvent-free formulation of paclitaxel encapsulated in albumin. It does not require
premedication with corticosteroids or antihistamines to prevent the risk of solvent-mediated
hypersensitivity reactions. This new formulation improves safety profile, allows higher
dosing with shorter infusion duration, and produces higher tumor drug concentration.
As neoadjuvant treatment does not only allow to compare competing treatment approaches with a
very high quality (homogenous treatment population, precise assessment of response by
histological assessment), but also to identify predictive markers, this trial will compare
weekly nab-paclitaxel with solvent-based paclitaxel at their currently optimal doses.
In case of HER2-positive tumor status patients receive Pertuzumab and Trastuzumab
additionally.
Primary Objectives:
To compare the pathological complete response (pCR=ypT0 ypN0) rates of neoadjuvant treatment
of nab-paclitaxel with solvent-based paclitaxel as part of neoadjuvant treatment of operable
or locally advanced primary breast cancer
Secondary Objectives:
- To assess the pCR rates per arm separately for the stratified subpopulations.
- To determine the rates of ypT0/is ypN0; ypT0 ypN0/+; ypT0/is ypN0/+; ypT(any) ypN0; and
regression grades.
- To determine the response rates of the breast tumor and axillary nodes based on physical
examination and imaging tests (sonography, mammography, or MRI) after treatment in both
arms.
- To assess clinical response rate after taxane in both groups
- To determine the breast conservation rate after each treatment.
- To assess the toxicity and compliance.
- To assess the time of onset of grade 3 neuropathy
- To assess the time of resolution of grade 3/4 neuropathy to at least grade 1
- To determine loco-regional invasive recurrence free survival (LRRFS),
distant-disease-free survival (DDFS), invasive disease-free survival (IDFS), and overall
survival (OS) in both arms and according to stratified subpopulations.
- To assess regional recurrence free survival (RRFS) in patients with initial
node-positive axilla converted to negative at surgery and treated with sentinel node
biopsy alone.
- To determine the pCR rate and local recurrence free survival (LRFS) in patients with a
clinical complete response (cCR) and a negative core biopsy before surgery.
- To examine and compare pre-specified molecular markers such as SPARC, gp60, calveoline 1
and other markers potentially differentially predicting efficacy of nab-paclitaxel and
solvent-based paclitaxel on core biopsies before, during and after chemotherapy.
Objectives of Substudies:
- To assess, characterize, and correlate circulating tumor cells and proteins with the
effect of treatment (CTC Substudy).
- To correlate Single Nucleotide Polymorphisms (SNPs) of genes with the associated
toxicity and histologically assessed treatment effect (Pharmacogenetic substudy)
- To assess ovarian function measured by amenorrhea rate in correlation with changes in
E2, FSH, LH , Anti-Müller Hormone, ultrasound-follicle count in patients aged < 45
years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00344071 -
Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
|
N/A | |
Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02221999 -
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02324088 -
Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
|
Phase 3 | |
Completed |
NCT00003199 -
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
|
Phase 2 | |
Terminated |
NCT00016276 -
Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
|
Phase 3 | |
Recruiting |
NCT01880385 -
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06131632 -
Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy
|
N/A | |
Completed |
NCT00513695 -
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
|
Phase 2 | |
Completed |
NCT00340158 -
Establishing an Inflammatory Breast Cancer Registry
|
N/A | |
Recruiting |
NCT04636710 -
Refining Local-Regional Therapy for IBC
|
N/A | |
Active, not recruiting |
NCT05415215 -
A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer
|
Phase 3 | |
Recruiting |
NCT04030507 -
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
|
N/A | |
Recruiting |
NCT03515798 -
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02879513 -
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
|
Phase 3 | |
Completed |
NCT02199418 -
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02623972 -
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
|
Phase 2 | |
Recruiting |
NCT00891280 -
Dose-escalation Study of Oral CX-4945
|
Phase 1 | |
Completed |
NCT00049114 -
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04660929 -
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
|
Phase 1 |